Persistence of antibodies to meningococcal IgA1 protease versus decay of antibodies to group A polysaccharide and Opc protein

Vaccine

Volumn 15, Issue 2, 1997, Pages 209-219

  Thiesen, Burghard ^a   Greenwood, Brian ^b,c   Brieske, Norbert ^a   Achtman, Mark ^a  

^a MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^b MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antibody decline; Antibody persistence; Synthetic peptides

Indexed keywords

BACTERIAL POLYSACCHARIDE; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MENINGOCOCCUS VACCINE; PROTEINASE; SYNTHETIC PEPTIDE;

ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAMBIA; HUMAN; HUMAN EXPERIMENT; MALE; MENINGITIS; MENINGOCOCCEMIA; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PRIORITY JOURNAL; VACCINATION;

AMINO ACID SEQUENCE; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ANTIGENS, SURFACE; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; INFANT; MOLECULAR SEQUENCE DATA; NEISSERIA MENINGITIDIS; POLYSACCHARIDES, BACTERIAL; SERINE ENDOPEPTIDASES;

EID: 0031081383     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00138-7     Document Type: Article

References (53)

1. 1 Achtman, M. Global epidemiology of meningococcal disease. In: Meningococcal Disease (Ed. Cartwright, K.). John Wiley and Sons Ltd, Chichester, England, 1995, pp. 159-175
2. 2 Wang, J., Caugant, D.A., Li, X. et al. Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in China. Infect. Immun. 1992, 60, 5267-5282
3. 3 Binkin, N. and Band, J. Epidemic of meningococcal meningitis in Bamako, Mali: epidemiological features and analysis of vaccine efficacy. Lancet 1982, ii, 315-318
4. 4 Wahdan, M.H., Rizk, R., El-Akadd, A.M. et al. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull. Wld Hlth Organ. 1973, 48, 667-673
5. 5 Erwa, H.H., Haseeb, M.A., Idris, A.A., Lapeyssonnie, L., Sanborn, W.R. and Sippel, J.E. A serogroup A meningococcal polysaccharide vaccine. Studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A. Bull. Wld Hlth Organ. 1973, 49, 301-305
6. 6 Bosmans, E., Vimont-Vicary, R., André, F.E., Crooy, P.J., Roelants, P. and Vandepitte, J. Protective efficacy of a bivalent (A+C) meningococcal vaccine during a cerebrospinal meningitis epidemic in Rwanda. Ann. Soc. Belg. Med. Trop. 1980, 60, 297-306
7. 7 Greenwood, B.M., Smith, A.W. and Hassan-King, M. The efficacy of meningococcal polysaccharide vaccine in preventing group A meningococcal disease in The Gambia, West Africa. Trans. R. Soc. Trop. Med. Hyg. 1986, 80, 1006-1007
8. 8 Gold, R., Lepow, M.L., Goldschneider, I., Draper, T. and Gotschlich, E.G. Antibody responses of human infants to three doses of group A Neisseria meningitidis polysaccharide vaccine administered at two, four, and six months of age. J. Infect. Dis. 1978, 138, 731-735
9. 9 Goldschneider, I., Lepow, M.L., Gotschlich, E.G., Mauck, F.T., Bachl, F. and Randolph, M. Immunogenicity of group A and group C meningococcal polysaccharides in human infants. J. Infect. Dis. 1973, 128, 769-776
10. 10 Twumasi, P.A.Jr, Kumah, S., Leach, A. et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J. Infect. Dis. 1995, 171, 632-638
11. 11 Käyhty, H., Karanko, V., Peltola, H., Sarna, S. and Mäkelä, P.H. Serum antibodies to capsular polysaccaride vaccine of group A Neisseria meningitidis followed for three years in infants and children. J. Infect. Dis. 1980, 142, 861-868
12. 12 Mäkelä, P.H., Peltola, H., Käyhty, H. et al. Polysaccharide vaccines to group A Neisseria meningitidis and Haemophilus influenzae type b: a field trial in Finland. J. Infect. Dis. 1977, 136, 43-50
13. 13 Rautonen, N., Pelkonen, J., Sipinen, S., Käyhty, H. and Mäkelä, O. Isotype concentrations of human antibodies to group A meningococcal polysaccharide. J. Immun. 1986, 137, 2670-2675
14. 14 Biselli, R., Casapollo, L., D'Amelio, R., Salvato, S., Matricardi, P.M. and Brai, M. Antibody response to meningococcal polysaccharides A and C in patients with complement defects. Scand. J. Immun. 1993, 37, 644-650
15. 15 Zangwill, K.M., Stout, R.W., Carlone, G.M. et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J. Infect. Dis. 1994, 169, 847-852
16. 16 Brandt, B.L. and Artenstein, M.S. Duration of antibody response after vaccination with group C Neisseria meningitidis polysaccharide. J. Infect. Dis. 1975, 131, S69-S72
17. 17 Gold, R., Lepow, M.L., Coldschneider, I., Draper, T.F. and Gotschlich, E.C. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J. Infect. Dis. 1979, 140, 690-697
18. 18 Peltola, R., Mäkelä, P.M., Käyhty, M.H. et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N. Engl. J. Med. 1977, 297, 686-691
19. 19 Greenwood, B.M., Whittle, H.C., Bradley, A.K., Fayet, MT. and Gilles, H.M. The duration of the antibody response to meningococcal vaccination in an African village. Trans. R. Soc. Trop. Med. Hyg. 1980, 74, 756-760
20. 20 Mohammed, I., Onyemelukwe, G.G., Obineche, E.N., Gupta, N. and Oyeyinka, G.O. Control of epidemic meningococcal meningitis by mass vaccination II. Persistence of antibody four years after vaccination. J. Infect. 1984, 9, 197-202
21. 21 Ceesay, S.J., Allen, S.J., Menon, A. et al. Decline in meningococcal antibody levels in African children five years after vaccination and the lack of an effect of booster immunization. J. Infect. Dis. 1993, 167, 1212-1216
22. 22 Wahdan, M.H., Sallam, S.A., Hassan, M.N. et al. A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria. Bull. Wld Hlth Organ. 1977, 55, 645-651
23. 23 Reingold, A.L., Broome, C.V., Hightower, A.W. et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985, ii, 114-118
24. 24 Hassan-King, M.K.A., Wall, R.A. and Greenwood, B.M. Meningococcal carriage, meningococcal disease and vaccination. J. Infect. 1988, 16, 55-59
25. 25 Crowe, B.A., Wall, R.A., Kusecek, B. et al. Clonal and variable properties of Neisseria meningitidis isolated from cases and carriers during and after an epidemic in the Gambia. West Africa. J. Infect. Dis. 1989, 159, 686-700
26. 26 Morelli, G., del Valle, J., Lammel, C.J. et al. Immunogenicity and evolutionary variability of epitopes within IgA1 protease from serogroup A Neisseria meningitidis. Molec. Microbiol. 1994, 11, 175-187
27. 27 Achtman, M., Wall, R.A., Bopp, M. et al. Variation in Class 5 protein expression by serogroup A meningococci during a meningitis epidemic. J. Infect. Dis. 1991, 164, 375-382
28. 28 Brooks, G.F., Lammel, C.J., Blake, M.S., Kusecek, B. and Achtman, M. Antibodies against IgA1 protease are stimulated both by clinical disease and by asymptomatic carriage of serogroup A Neisseria meningitidis. J. Infect. Dis. 1992, 166, 1316-1321
29. 29 Rosenqvist, E., Høiby, E.A., Wedege, E., Kusecek, B. and Achtman, M. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J. Infect. Dis. 1993, 167, 1065-1073
30. 30 Gotschlich, E.C. Development of polysaccharide vaccines for the prevention of meningococcal disease. Monograph. Allergy 1975, 9, 245-258
31. 31 Achtman, M., Neibert, M., Crowe, B.A. et al. Purification and characterization of eight class 5 outer membrane protein variants from a clone of Neisseria meningitidis serogroup A. J. Exp. Med. 1988, 168, 507-525
32. 32 Butz, S., Rawer, S., Rapp, W. and Birsner, U. Immunization and affinity purification of antibodies using resin-immobilized lysine-branched synthetic peptides. Peptide Res. 1994, 7, 20-23
33. 33 Wang, J., Caugant, D.A., Morelli, G., Koumaré, B. and Achtman, M. Antigenic and epidemiological properties of the ET-37 complex of Neisseria meningitidis. J. Infect. Dis. 1993, 167, 1320-1329
34. 34 de Cossio, M.E.F., Ohlin, M., Llano, M. et al. Human monoclonal antibodies against an epitope on the class 5c outer membrane protein common to many pathogenic strains of Neisseria meningitidis. J. Infect. Dis. 1992, 166, 1322-1328
35. 35 Fomsgaard, A. and Dinesen, B. ELISA for human IgG and IgM anti-lipopolysaccharide antibodies with indirect standardization. J. Immunoassay 1987, 8, 333-350
36. 36 Carlone, G.M., Frasch, C.E., Siber, G.R. et al. Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay. J. Clin. Microbiol. 1992, 30, 154-159
37. 37 Pohlner, J., Halter, R., Beyreuther, K. and Meyer, T.F. Gene structure and extracellular secretion of Neisseria gonorrhoeae IgA protease. Nature 1987, 325, 458-462
38. 38 Zollinger, W.D. and Boslego, J.W. A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies. J. Immun. Meth. 1981, 46, 129-140
39. 39 Mäkelä, O. and Péterfy, F. Standard sera in solid-phase immunoassays. Eur. J. Immun. 1983, 13, 815-819
40. 40 Plikaytis, B.D., Holder, P.F., Pais, L.B., Maslanka, S.E., Gheesling, L.L. and Carlone, G.M. Determination of parallelism and nonparalielism in bioassay dilution curves. J. Clin. Microbiol. 1994, 32, 2441-2447
41. 41 Gotschlich, E.C., Rey, M., Triau, R. and Sparks, K.J. Quantitative determination of the human immune response to immunization with meningococcal vaccines. J. Clin. Invest. 1972, 51, 89-96
42. 42 Lepow, M.L., Goldschneider, I., Gold, R., Randolph, M. and Gotschlich, E.G. Persistence of antibody following immunization of children with group A and C meningococcal polysaccharide vaccines. Pediatrics 1977, 60, 673-680
43. 43 Brown, P., Gajdusek, D.C. and Tsai, T. Persistence of measles antibody in the absence of circulating natural virus five years after immunization of an isolated virgin population with Edmonston B vaccine. Am. J. Epidemiol. 1969, 90, 514-518
44. 44 Krugman, S. Further-attenuated measles vaccine: characteristics and use. Rev. Infect. Dis. 1983, 5, 477-481
45. 45 Gunn, T.R. and Woodfield, D.G. The persistence of anti-hepatitis B surface antibodies to three years of age: is a hepatitis B vaccine booster required?. N. Z. Med. J. 1993, 106, 499-501
46. 46 Faden, H., Duffy, L., Sun, M. and Shuff, C. Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines. J. Infect. Dis. 1993, 168, 452-454
47. 47 King, J.C.Jr, Lichenstein, R., Feigelman, S., Luna, C., Permutt, T.J. and Patel, J. Measles, mumps, and rubella antibodies in vaccinated Baltimore children. Am. J. Dis. Child 1993, 147, 558-560
48. 48 Mulholland, E.K., Todd, J., Rowe, M. et al. Persistence of antibody at 18 months following vaccination of young Gambian infants with PRP-OMPC Haemophilus influenzae type b conjugate vaccine. Ann. Trop. Paediatr. 1993, 13, 153-158
49. 49 Calandra, G.B., Lukacs, L.J., Jonas, L.C. et al. Anti-PRP antibody levels after a primary series of PRP-OMPC and persistence of antibody titres following primary and booster doses. Vaccine 1993, 11 Suppl. 1, S58-S62
50. 50 Rumke, H.C., Schlumberger, M., Floury, B., Nagel, J. and van Steenis, B. Serological evaluation of a simplified immunization schedule using quadruple DPT-polio vaccine in Burkina Faso. Vaccine 1993, 11, 1113-1118
51. 51 Isacson, J., Trollfors, B., Taranger, J. et al. Safety, immunogenicity and an open, retrospective study of efficacy of a monocomponent pertussis toxoid vaccine in infants. Pediatr. Infect. Dis. J. 1994, 13, 22-27
52. 52 Anderson, E.L., Bowers, T., Mink, C.M. et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect. Immun. 1994, 62, 3391-3395
53. 53 Bijimer, H.A., Lloyd Evans, N., Campbell, H. et al. Carriage of Haemophilus influenzae in healthy Gambian children. Trans. R. Soc. Trop. Med. Hyg. 1989, 83, 831-835